DK3402515T3 - Forbedrede fremgangsmåder til monitorering af et individs immunstatus - Google Patents
Forbedrede fremgangsmåder til monitorering af et individs immunstatus Download PDFInfo
- Publication number
- DK3402515T3 DK3402515T3 DK17738918.6T DK17738918T DK3402515T3 DK 3402515 T3 DK3402515 T3 DK 3402515T3 DK 17738918 T DK17738918 T DK 17738918T DK 3402515 T3 DK3402515 T3 DK 3402515T3
- Authority
- DK
- Denmark
- Prior art keywords
- monitoring
- individual
- immune status
- improved procedures
- procedures
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277801P | 2016-01-12 | 2016-01-12 | |
| US201662300708P | 2016-02-26 | 2016-02-26 | |
| PCT/US2017/013169 WO2017123741A1 (en) | 2016-01-12 | 2017-01-12 | Improved methods for monitoring immune status of a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3402515T3 true DK3402515T3 (da) | 2021-11-15 |
Family
ID=59312140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17738918.6T DK3402515T3 (da) | 2016-01-12 | 2017-01-12 | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11698369B2 (da) |
| EP (2) | EP4079320A1 (da) |
| JP (2) | JP7011600B2 (da) |
| CA (1) | CA3010019A1 (da) |
| DK (1) | DK3402515T3 (da) |
| ES (1) | ES2898329T3 (da) |
| WO (1) | WO2017123741A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10126301B2 (en) | 2013-02-08 | 2018-11-13 | Institute For Myeloma & Bone Cancer Research | Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma |
| DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
| WO2018231944A1 (en) | 2017-06-13 | 2018-12-20 | Berenson James R | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| US11505614B2 (en) * | 2018-09-28 | 2022-11-22 | Amgen Inc. | Antibodies binding to soluble BCMA |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4493795A (en) | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US6383480B1 (en) | 1996-07-10 | 2002-05-07 | Meiji Milk Products, Co., Ltd. | Composition comprising midkine or pleiotrophin protein and method of increasing hematopoietic cells |
| GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6355623B2 (en) | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| AU2002306596B2 (en) | 2001-02-27 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| EP1436323A4 (en) | 2001-09-06 | 2005-03-16 | Biogen Idec Inc | CRYSTALLINE STRUCTURE OF BAFF AND USE FOR THE DESIGN OF MEDICAMENTS |
| CA2523776A1 (en) | 2003-03-07 | 2004-09-23 | Xencor, Inc. | Baff mutants with at least one amino acid substitution and methods of their production |
| US20080050381A1 (en) | 2004-08-31 | 2008-02-28 | Tsutomu Takeuchi | Antihuman Baff Antibody |
| WO2006044582A2 (en) | 2004-10-13 | 2006-04-27 | The Washington University | Use of baff to treat sepsis |
| WO2006067210A1 (en) * | 2004-12-23 | 2006-06-29 | Laboratoires Serono S.A. | Bcma polypeptides and uses thereof |
| WO2007053732A2 (en) | 2005-11-01 | 2007-05-10 | Mayo Foundation For Medical Education And Research | Promoter polymorphisms of the blys gene and use in diagnostic methods |
| WO2007056288A2 (en) | 2005-11-08 | 2007-05-18 | Biogen Idec Ma Inc. | Methods of evaluating baff |
| CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| EP2348023B9 (en) | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| US20080058316A1 (en) | 2006-02-27 | 2008-03-06 | The Johns Hopkins University | Cancer treatment with gama-secretase inhibitors |
| DK2016102T3 (da) | 2006-05-03 | 2012-07-02 | Us Gov Health & Human Serv | Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse |
| CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| NZ612647A (en) | 2009-03-10 | 2015-03-27 | Biogen Idec Inc | Anti-bcma antibodies |
| US9101559B2 (en) | 2009-05-08 | 2015-08-11 | New York University | Leukemic cell CNS infiltration controlled by notch-induced chemotaxis |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| MX351069B (es) | 2011-05-27 | 2017-09-29 | Glaxo Group Ltd | Proteinas de union abcma (cd269/tnfrsf17). |
| JP6694712B2 (ja) * | 2012-11-01 | 2020-05-20 | マックス−デルブルック−セントラム フアー モレキュラーレ メデジン | Ｃｄ２６９（ｂｃｍａ）に対する抗体 |
| EP2762496A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| US10126301B2 (en) | 2013-02-08 | 2018-11-13 | Institute For Myeloma & Bone Cancer Research | Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma |
| EP3102238A1 (en) | 2014-01-20 | 2016-12-14 | Gilead Sciences, Inc. | Therapies for treating cancers |
| US10144782B2 (en) | 2014-04-30 | 2018-12-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Humanized antibodies against CD269 (BCMA) |
| US10363260B2 (en) | 2014-05-28 | 2019-07-30 | Oncotracker, Inc. | Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| US20170224730A1 (en) | 2014-06-10 | 2017-08-10 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
| HRP20220738T1 (hr) | 2014-08-11 | 2022-08-19 | Acerta Pharma B.V. | Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1 |
| US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| DK3227432T3 (en) | 2014-12-05 | 2023-10-23 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| US11060150B2 (en) | 2015-03-17 | 2021-07-13 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating cancer |
| US20180214553A1 (en) | 2015-07-24 | 2018-08-02 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| ES2814550T3 (es) | 2015-08-17 | 2021-03-29 | Janssen Pharmaceutica Nv | Anticuerpos anti-BCMA, moléculas que se unen a antígeno biespecífico que se unen a BCMA y CD3, y usos de los mismos |
| BR112018008799A2 (pt) * | 2015-10-30 | 2019-01-15 | Glaxosmithkline Ip Dev Ltd | método de prognóstico |
| DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
| WO2017201040A1 (en) | 2016-05-16 | 2017-11-23 | Berenson James Richard | Improved methods for monitoring immune status of a subject |
| CN110267677A (zh) | 2016-08-01 | 2019-09-20 | 诺华股份有限公司 | 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症 |
| WO2018085363A2 (en) | 2016-11-02 | 2018-05-11 | Berenson James Richard | Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma |
| WO2018231944A1 (en) | 2017-06-13 | 2018-12-20 | Berenson James R | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| US20200179451A1 (en) | 2017-07-19 | 2020-06-11 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| WO2020092792A2 (en) | 2018-10-31 | 2020-05-07 | Oncotracker, Inc. | Method of enhancing immune-based therapy |
-
2017
- 2017-01-12 DK DK17738918.6T patent/DK3402515T3/da active
- 2017-01-12 EP EP21190326.5A patent/EP4079320A1/en active Pending
- 2017-01-12 CA CA3010019A patent/CA3010019A1/en active Pending
- 2017-01-12 WO PCT/US2017/013169 patent/WO2017123741A1/en active Application Filing
- 2017-01-12 JP JP2018555442A patent/JP7011600B2/ja active Active
- 2017-01-12 ES ES17738918T patent/ES2898329T3/es active Active
- 2017-01-12 EP EP17738918.6A patent/EP3402515B8/en active Active
- 2017-01-12 US US16/068,831 patent/US11698369B2/en active Active
-
2022
- 2022-01-14 JP JP2022004416A patent/JP2022058619A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190049437A1 (en) | 2019-02-14 |
| JP7011600B2 (ja) | 2022-01-26 |
| EP3402515B8 (en) | 2021-12-08 |
| CA3010019A1 (en) | 2017-07-20 |
| EP3402515A4 (en) | 2019-07-10 |
| JP2019508714A (ja) | 2019-03-28 |
| EP3402515A1 (en) | 2018-11-21 |
| US11698369B2 (en) | 2023-07-11 |
| JP2022058619A (ja) | 2022-04-12 |
| ES2898329T3 (es) | 2022-03-07 |
| EP4079320A1 (en) | 2022-10-26 |
| WO2017123741A1 (en) | 2017-07-20 |
| EP3402515B1 (en) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3371619T3 (da) | Detektering af et ubemandet luftfartøj | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3300500T3 (da) | Triazolagonister af apj-receptoren | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3481838T3 (da) | Nye fremgangsmåder til fremstillingen af oligonukleotider | |
| DK3940352T3 (da) | Fremgangsmåde til diagnosticering af vægte | |
| DK3126373T3 (da) | Fremgangsmåde til fremstilling af amg 416 | |
| DK3461891T3 (da) | Nedstrømsbehandling af en alkalisk phosphatase | |
| DK3372585T3 (da) | Fremgangsmåde til fremstillingen af en diarylthiohydantoinforbindelse | |
| DK3365563T3 (da) | Forbindelseskomponent | |
| DK3507408T3 (da) | Fremgangsmåde til fremstilling af nonwoven | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| DK3001700T3 (da) | Positioneret høresystem | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DE112016004797T8 (de) | Zentrifugalkompressor | |
| DK3191498T3 (da) | Fremgangsmåde til fremstilling af 2'-o-fucosyllactose | |
| DK3166611T3 (da) | Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer | |
| DK3438103T3 (da) | Griseofulvinforbindelse | |
| DK3402515T3 (da) | Forbedrede fremgangsmåder til monitorering af et individs immunstatus | |
| DK3273262T3 (da) | Sekundær monoimpuls-overvågningsradar | |
| DK3120153T3 (da) | Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid | |
| DK3141052T3 (da) | Konfiguration af beskyttelsesperiode til LTE HD-FDD |